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Abstract
Summary There is a huge prevalence of hypovitaminosis D
in the Indian population. We studied the efficacy and safety
of oral vitamin D supplementation in apparently healthy
adult women. Monthly cholecalciferol given orally,
60,000 IU/month during summers and 120,000 IU/month
during winters, safely increases 25-hydroxyvitamin D (25
(OH)D) levels to near normal levels.
Introduction There is a huge burden of hypovitaminosis D in
the Indianpopulation.Thecurrent recommendationfor vitamin
D supplementation is not supported by sufficient evidence.
Methods Study subjects included 100 healthy adult women
of reproductive age group from hospital staff. They were
randomized into group A (control) and group B (supple-
ment) by simple randomization. Group B received
60,000 IU of cholecalciferol/month administered orally for
3 months, and then group A received 60,000 IU and group
B 120,000 IU/month for 6 months.
Results Mean baseline 25(OH)D level was 4.5±3.1 ng/ml
and parathyroid hormone level was 50±25 pg/ml. In group B,
25(OH)D levels increased from 4.8±3.5 to 31.6±15.5 ng/ml
(P<0.001) in 3 months. Interestingly, the increase, although
of lower magnitude, was also observed in control group A,
from 4.5±3.4 ng/ml (in spring) to 10.8±7.2 ng/ml (in
summer; P<0.001). In group A (60,000 IU/month), mean 25
(OH)D level had increased to 22.3±12.4 ng/ml (P<0.001)at
9 months (winter). In group B (120,000 IU/month), 25(OH)
D levels were maintained at 30.7±12.8 ng/ml at 9 months
(winter).
Conclusion Our data show that monthly administration of
60,000 IU cholecalciferol in healthy subjects with hypo-
vitaminosis D may suffice in summer months, but higher
doses may be more appropriate during winter months.
Keywords HypovitaminosisD.Cholecalciferol.25(OH)D
Introduction
Vitamin D is widespread in nature and photosynthesized in
most plants and animals exposed to sunlight [1]. Its major
role in vertebrate animals and humans is to increase the
absorption of calcium and phosphate for mineralization of
the skeleton. In vitamin D-deficient children, the cartilage is
not calcified, causing rickets. In adults with vitamin D
deficiency, the newly formed bone matrix (the osteoid) is
not mineralized, causing osteomalacia [2].
Synthesis of vitamin D takes place in the skin under the
effect of sunlight. The Indian subcontinent is situated
between 8.4° N and 37.6° N latitude and has adequate
sunshine throughout the year. Despite this fact, studies have
shown widespread prevalence of hypovitaminosis D that
may have an adverse impact on bone health [3–7]. Even
frank nutritional osteomalacia has been reported in urban
Indians [8]. Avoidance of sunlight, cultural and clothing
practices, and skin pigment are factors contributing to
vitamin D deficiency. Increasing urbanization that results in
poor outdoor activity and greater pollution may further
aggravate the problem [9].
Severe vitamin D deficiency results in clinically apparent
metabolic bone disease, i.e., rickets and osteomalacia.
Subclinical vitamin D deficiency or insufficiency can result
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DOI 10.1007/s11657-009-0026-8in decrease in overall bone mass and, therefore, an
increased risk of osteoporosis [3, 10]. Adequate replace-
ment with vitamin D can increase the bone mass and
decrease the risk of fractures [11].
The optimal dose of vitamin D intake for the general
population remains a subject of controversy. Experts now
feel that 25-hydroxyvitamin D (25(OH)D) level of 30 ng/ml
is required for maintaining optimal skeletal health [12].
Average 25(OH)D levels in Indians have been reported to
be between 3 and 10 ng/ml in various studies especially
from north India. The recommended doses of vitamin D
(200–400 IU/day) intake are grossly inadequate to bring
such low 25(OH)D levels to the desired levels [13–17].
This study was, therefore, undertaken to assess the efficacy
and safety of cholecalciferol supplementation administered
orally, 60,000 and 120,000 IU/month equivalent to
2,000 IU/day (50 μg/day) and 4,000 IU/day (100 μg/day),
respectively, in apparently healthy Indian women. This
dose was chosen because this preparation is commonly and
widely used in Indian setting, and the dose seems to be in
agreement with the current suggestions available on vitamin
D supplementation in the literature [14]. According to
present studies, a dose as high as 10,000 IU/day is likely to
pose no risk of adverse effects [18].
Methods
Subjects
Study subjects included 100 apparently healthy adult Indian
women of reproductive age group. They were all employ-
ees of Indraprastha Apollo Hospital (nurses, doctors, and
administrative staff) who volunteered to participate in the
study. None of these subjects had clinical signs and
symptoms of overt metabolic bone disease such as bone
pains, myopathy, or fractures. Study subjects included
menstruating women >18 years of age.
Exclusion criteria included history of renal failure, liver
failure, malabsorption disorder, known disorders of parathy-
roid function, hypercalcemia, hypocalcemia, known history of
vitamin D intoxication and granulomatous diseases, and
history of drug ingestion known to affect vitamin D metabo-
lism (steroids, phenytoin, carbamazepine, and rifampicin).
Daily intake of dietary calcium was calculated from a food
frequency questionnaire. Sunlight exposure was assessed by
taking history of duration of daily sunlight exposure.
Study design and conduct
Study subjects were randomized into two groups: group A
and group B by simple randomization. They were randomly
assigned to receive either vitamin D supplementation with
cholecalciferol 60,000 IU/month administered orally or no
supplementation in a 1:1 ratio, during the month of March
(spring). This randomization was done regardless of their
baseline 25(OH)D status. Group B received one sachet of
cholecalciferol (containing 1,500 μg/60,000 IU vitamin D3,
Cadila Pharmaceutical, India) per month, dissolved in a
glass of milk, for 3 months. Subjects were made to drink
this milk once a month under observation (Fig. 1).
The baseline results showed presence of hypovitami-
nosis D in all the study subjects (25(OH)D <20 ng/ml).
At 3 months of review by the ethics committee, it was
suggested that the study design be modified since it
would be unethical to keep the subjects in group A, with
significant hypovitaminosis D, deprived of vitamin D. In
view of this, after 3 months, group A (low-dose group)
received one sachet of cholecalciferol (60,000 IU) and
group B (high-dose group) received two sachets of
cholecalciferol (120,000 IU) once a month for 6 months.
Vitamin D doses are usually described in their daily
amounts; we, therefore, express the monthly doses given
here in their average daily amounts of 2,000 IU/day
(50 μg/day) and 4,000 IU/day (100 μg/day). Blood and
urine samples were drawn at 3 months (June, summer)
and again at 9 months (December, winter).
Daily dietary intake of calcium was measured by semi-
quantitative food frequency questionnaire. All subjects were
given diet charts that provided 800–1,000 mg of calcium/day.
The study protocol including vitamin D supplementation was
approved by the ethics committee of our institution, and
informed consent was obtained from all the subjects.
Follow-up, compliance, and actual number of subjects
analyzed
At baseline, there were 100 subjects (A—50, B—50). Nine
subjects lost follow-up at 3 months (A—42, B—49), and
31 subjects lost follow-up at 9 months (A—32, B—37).
The reason for drop out was migration.
Biochemical estimations
Blood samples were drawn after an overnight fast between
0800 and 1000 hours at 0, 3, and 9 months for calcium,
phosphorus, alkaline phosphatase, 25(OH)D, parathyroid
hormone (PTH) estimation, and urine samples for calcium,
phosphorus, and creatinine estimation. Samples for 25(OH)D
and intact PTH were cold-centrifuged for 15 min at 8°C, and
serum was stored in plastic aliquots at −20°C. The frozen
serum was then transported on dry ice to Sanjay Gandhi Post
Graduate Institute, Lucknow, India. Serum 25(OH)D concen-
trations were estimated by radioimmunoassay (Diasorin,
Stillwater, MN 55082-0285, USA; kit, normal range 9.3–
37.9 ng/ml). The sensitivity of this assay is 1.5 ng/ml, within-
48 Arch Osteoporos (2009) 4:47–53run coefficient of variation (CV) is 10.5%, and the total
imprecision CV is 8.2% at 22.7 ng/ml. Vitamin D deficiency,
insufficiency, and sufficiency were defined based on serum 25
(OH)D concentrations as <20, 20–30, and >30 ng/ml,
respectively [13–15]. The assays were analyzed in duplicate.
Serum intact PTH was measured by using an immunoradio-
metric assay (Diasorin; 10–55 pg/ml). However, 10–55 pg/ml
is the locally determined PTH range used at SGPGI
Laboratory, which has been analyzing these tests for several
years. Analytical sensitivity of the assay is 0.7 pg/ml. Intra-
assay variation is 3.6% at mean value of 26 pg/ml, and inter-
assay variation is 3.4% at mean value of 49 pg/ml. Serum
total calcium, inorganic phosphorus, and alkaline phosphatase
were estimated by colorimetric method using commercial kits.
Statistical analysis
Results are expressed as means ± SDs. Analysis was
performed using SPSS software (version 12.0). Group
means were compared by using parametric (paired t test).
Nonparametric test (Wilcoxon-signed ranks test) was used
to compare various indices at three different time intervals
because the variables did not show normal distribution. A
P value of <0.05 was considered significant.
Results
Baseline characteristics
One hundred healthy volunteers were recruited during the
spring month of March 2007. Mean age and body mass
index of the females was 26.82±5.14 years and 22.34±
3.61 kg/m
2, respectively. Mean dietary calcium intake was
525±176.53 mg/day. Range for daily calcium intake
estimate was 200–1,200 mg/day. Mean daily sunlight
exposure was 15±5 min/day. The average body surface
area exposed during winters was 10% and during summers
20%. None of the study subjects had any signs and
symptoms of vitamin D deficiency.
Mean 25(OH)D was 4.7±3.4 ng/ml and PTH was 50±
24 pg/ml. All our subjects had hypovitaminosis D (<20 ng/
ml). Ninety-four percent of the subjects in group A and
90.6% of the subjects in group B had 25(OH)D levels
<10 ng/ml. There were no between-group differences in
age, calcium intake, sunlight exposure, and baseline
biochemical bone parameters (Table 1).
At 3 months follow-up
Blood and urine samples were drawn after 3 months, during
the month of June (summer). In group B (high-dose group),
serum 25(OH)D levels increased from 4.8±3.5 ng/ml
(March) to 31.6±15.5 ng/ml (June), after 3 months of
supplementation with 60,000 IU of cholecalciferol per
month administered orally (P<0.001; Fig. 2a). This
statistically significant increase had brought down the
percentage of subjects with 25(OH)D <20 ng/ml from
100% at baseline to 30% after supplementation, and only
four subjects (8.2%) had 25(OH)D <10 ng/ml. The
associated decrease in serum intact PTH and serum total
alkaline phosphatase level was also significant (P<0.05).
In group A (low-dose group), increase in serum 25(OH)
D levels was also observed, from 4.5±3.4 (March) to 10.8±
7.2 ng/ml (June; P<0.001). This increase was found to be
significant (P<0.001) but was markedly less as compared
Subjects and methods :
Cholecalciferol supplementation
Recruited apparently healthy women
Initial randomization
Group A
No supplementation
Group B
60,000 units of cholecalciferol 
once a month
Interim analysis:
• All had hypovitaminosis D
Subsequent groups
Group A
60,000 units once a month
Group B
1,20,000 units once a month
Fig. 1 Study design
Arch Osteoporos (2009) 4:47–53 49to that in group B (Fig. 2a). Ninety percent of the subjects in
groupAcontinuedtohave25(OH)D<20ng/ml.Interestingly,
significant decrease in serum intact PTH and serum total
alkaline phosphatase level was also observed. There was no
significant change observed in other biochemical variables.
After 6 months of supplementation (December)
At the end of 3 months, group A received 60,000 IU and
group B received 120,000 IU of cholecalciferol once a
month administered orally for 6 months. Samples were
Table 1 Comparison of baseline parameters between group A and group B
Variable Group A (control), N=50 (mean ± SD) Group B (supplement), N=50 (mean ± SD)
Age (years) 26±6.32 27±6.16
Serum calcium (mg/dl) 9.06±0.40 9.10±0.38
Serum phosphorus (mg/dl) 3.84±0.55 4.0±0.60
Serum alkaline phosphatase (IU/l) 75±24 69±22
Serum creatinine (mg/dl) 0.67±0.11 0.68±0.11
25(OH)D (ng/ml) 4.5±3.4 4.8±3.5
PTH (pg/ml) 52±25 49±24
Between-group differences were not significant, P>0.05
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Fig. 2 a Change in 25(OH)D levels in groups A and B. b Change in PTH levels in groups A and B
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(winters).
In group A, 25(OH)D levels increased from 10.8±7.2 to
22.4±12.4 ng/ml (P<0.001) in 6 months (Fig. 2a). Serum
PTH levels declined from 43±22 to 21±9 pg/ml (P<0.001;
Fig. 2b), and serum calcium levels had increased (P=
0.001). Change in other biochemical parameters was not
found to be significant. Fifty-five percent of the subjects in
group A had 25(OH)D >20 ng/ml and 9.7% of the subjects
had 25(OH)D <10 ng/ml after 6 months of supplementation
with 60,000 IU of cholecalciferol once a month (Fig. 3).
In group B, 25(OH)D levels did not change after
6 months of supplementation with 120,000 IU of cholecal-
ciferol once a month. Mean 25(OH)D level at 3 months was
31.6±15.5 ng/ml and, at 9 months, was 30.7±12.8 ng/ml
(Fig. 2a). However, the percentage of subjects with 25(OH)
D >20 ng/ml had increased to 82% and only one subject
(2.7%) had 25(OH)D <10 ng/ml (Fig. 3). Serum PTH levels
reduced from 38±16 to 19±8 pg/ml (P<0.001; Fig. 2b).
Increase in serum calcium was found to be significant in
both groups (P<0.05), although it did not exceed the upper
limit of normal in any subject.
Discussion
The current study evaluates serum 25(OH)D and PTH
responses at 3 and 9 months after oral supplementation with
cholecalciferol once a month in apparently healthy adult
women of reproductive age group. Our data confirm high
prevalence of vitamin D deficiency in India, as shown in
previous studies [3–7]. This is despite the fact that India is a
tropical country with abundant sunshine. The increasing
awareness about widespread prevalence of vitamin D
deficiency has led to an ongoing debate regarding correc-
tive measures and adequate intake to correct hypovitami-
nosis D. Based on currently available evidence, serum 25
(OH)D level of 30 ng/ml provides several specific health
benefits like optimal bone mineral density, improved
muscle strength, and reduced risk of fall and fractures
[12]. The recommended daily intake of vitamin D has been
close to 10 μg (400 IU/day) until 1997 [17]. Various studies
have shown that this daily allowance is not sufficient [14–
17]. To achieve 25(OH)D level of 30 ng/ml, vitamin D
supplementation dose needs to be increased to 1,000–
4,000 IU/day [14, 19, 20]. Individuals with abundant
sunlight exposure can easily exhibit a serum 25(OH)D
>60 ng/ml which would be a physiologic supplement input
of vitamin D intake >100 μg (4,000 IU/day). Concerns
about safety of vitamin D when used in “higher” doses
have been largely dispelled with recent evidence that a
prolonged intake of even 250 μg (10,000 IU/day) of
vitamin D3 is likely to pose no risk of adverse effects [18].
This study evaluates the response to different monthly
doses of vitamin D. The study was carried out in New Delhi
(location—28.38°N,77.12°E). Thiscityexperiences marked
seasonal variations: spring—February to March, summer—
April to June, and winter—November to January. The zenith
angle is 84.5° in peak summer and 38.5° in peak winter.
Our results showed that 60,000 IU/month (2,000 IU/day)
of cholecalciferol supplementation administered orally for
3 months during summer increased 25(OH)D levels
dramatically to near normal levels in group B (4.8±3.5 to
31.6±15.5 ng/ml). A similar increase (5.4±3.0 to 33±
20.7 ng/ml) was demonstrated in an Indian study by
Goswami et al. [24]. However, the supplementation dose
used in their study was higher, 1,500 μg (60,000 IU) of
cholecalciferol per week (8,000 IU/day). This supplemen-
tation was given for a period of 2 months and evaluation
was done during winter months. Their study further showed
that these 25(OH)D levels again declined to suboptimal
levels, 1 year after discontinuation of vitamin D supple-
mentation. In another study by Veith et al. [22], 25(OH)D
levels increased effectively to high-normal concentrations
in practically all adults, and serum 25(OH)D levels
remained within the physiologic range following supple-
mentation with 100 μg (4,000 IU/day) of cholecalciferol for
6 months.
The study subjects in group A, who did not receive any
supplementation, also showed increase in 25(OH)D levels
(4.5±3.4 to 10.8±7.2 ng/ml) at 3 months. This was most
likely due to the effect of seasonal variation on 25(OH)D
levels since the initial samples were drawn in March
(spring), and the 3-month samples were drawn in June
(summer; zenith angle is 84.5° in peak summer). Sunlight
exposure during summer is more effective in raising 25
(OH)D levels [23]. This was also evident in an earlier study
from India which showed higher 25(OH)D concentrations
in summer (7.1 ng/ml) than in winters (3.1 ng/ml) [21].
However, the effect of supplementation in group B was
more marked as compared to the effect of season in both
groups (P<0.05; Table 2).
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Arch Osteoporos (2009) 4:47–53 51Interesting biochemical responses were seen after
6 months of cholecalciferol supplementation with
60,000 IU/month (group A) vs. 120,000 IU/month (group
B). In low-dose group A, 25(OH)D levels increased from
10.8±7.2 to 22.4±12.4 ng/ml (P<0.001) during the winter
months. This increase was less as compared to that
achieved in group B with the same dose for 3 months
during the summer (4.8±3.5 to 31.6±15.5 ng/ml; Fig. 2a).
This finding emphasizes the winter effect on the 25(OH)D
levels. Serum 25(OH)D levels have been shown to fall to
undetectable levels in Asian Indians during winters in
previous studies [21]. During winter, sunlight is less
effective in raising the 25(OH)D levels and levels tend to
decline.
A similar effect of season on response to vitamin D
supplementation was seen in group B as well. The initial
increase in 25(OH)D levels observed at 3 months (summer)
with vitamin D supplementation of 60,000 IU/month [4.8±
3.5 ng/ml (March) to 31.6±15.5 ng/ml (June)] did not
continue at 9 months (winter) [30.7±12.8 ng/ml], despite
an increase in the dose to 120,000 IU/month. However,
there was no decline and the initial 25(OH)D levels
achieved were maintained. Figure 2a shows this plateau in
25(OH)D levels. Thus, a drop in 25(OH)D levels during
winter in group B was prevented but at a dose which was
double of that used during summer. Therefore, our study
confirms the need for higher doses of vitamin D supple-
mentation during winter.
Our study also reconfirms the finding that the average
increment in serum 25(OH)D levels is inversely propor-
tional to the baseline 25(OH)D levels [19]. The same dose
of 50 μg/day produced different increments in groups A
and B. The average increment produced in group B (0.5 ng/
ml for every microgram of cholecalciferol administered
orally) at 3 months was similar to that reported earlier [13,
19, 25]. However, the increment in group A (0.2 ng/ml/μg)
at 9 months was less with the same dose. In addition to the
winter effect, this can be attributed to the higher baseline 25
(OH)D level in group A [13].
The increment in 25(OH)D levels although less was
seen in group A with 60,000 IU/month but was not seen
at all in group B with 120,000 IU/month during winter
months. Again, this can be explained on the basis of the
differences in the baseline 25(OH)D levels in the two
groups at 3 months. It has been reported that the average
increment in 25(OH)D levels is 0.3 ng/ml or less if the
baseline 25(OH)D level is >28 ng/ml [19]. The baseline
25(OH)D level in group B at 3 months was 31.6 ng/ml,
which explains for no increment response observed in this
group. In group A, the baseline 25(OH)D level at 3 months
was 10.8 ng/ml, much less than the optimal levels. This is
clearly demonstrated in Fig. 2a. Other studies have also
implied that plateau levels of 25(OH)D can occur within
5 months [20, 26].
Higher levels of 25(OH)D generally correlate with lower
concentration of PTH [26]. The present data confirm that
both doses of supplementation produced a significant
suppression of PTH, to about half of the baseline levels
(Fig. 2b). Lack of statistical significance in PTH between
the dose groups could be attributed to relatively small
sample sizes in this study (Table 2).
Serum calcium had increased in both groups at 9 months,
but the levels remained within the normal range. There was
no evidence of hypercalciuria as a result of long-term use of
vitamin D at a relatively high dose of either 60,000 IU/
month (2,000 IU/day) or 120,000 IU/month (4,000 IU/day).
This dose was similar to that required to achieve optimal 25
(OH)D levels in Caucasians [16]. According to Aloia et al.,
vitamin D dose of 95 µg/day (3,800 IU) for those above a
25(OH)D threshold of 22 ng/ml and a dose of 125 µg/day
(5,000 IU) for those below that threshold is required to
achieve 25(OH)D concentration of >30 ng/ml. Since our
study subjects had very low baseline 25(OH)D levels with
very limited sunlight exposure, the use of higher doses was
justified.
Our results showed that daily intake of 50 μg (2,000 IU)
of vitamin D (cholecalciferol) during summers would bring
serum 25(OH)D levels to the vitamin D-sufficient range in
most of the subjects at 3 months. This dose is presently
considered to be the safe upper limit of vitamin D intake
[14]. Our study also showed that in order to maintain
optimal vitamin D levels in winters, even higher doses of
100 μg (4,000 IU/day) are required. The 50-µg/day dosage
was effective at ensuring 25(OH)D concentrations of
≥20 ng/ml in 70% subjects during summer. The 100-µg/
day dosage was effective at ensuring 25(OH)D concen-
trations of ≥20 ng/ml in 81.8% of the same subjects during
winter, similar to that reported by Veith et al. [22]. Our
results are similar to those of other studies showing higher
25(OH)D levels with 4,000 IU of oral vitamin D per day
with no risk of hypercalcemia or hypercalciuria [20, 22,
27].
Table 2 Biochemical measurements in groups A and B after vitamin
D supplementation
Group A Group B P value
3 months (June)
25(OH)D (ng/ml) 10.8±7.2 31.6±15.5 <0.001
PTH (pg/ml) 43±22 38±16 0.356
Serum calcium (mg/dl) 9.01±0.64 9.14±0.38 0.38
9 months (December)
25(OH)D (ng/ml) 22.4±12.4 30.7±12.8 <0.001
PTH (pg/ml) 21±9 19±8 0.480
Serum calcium (mg/dl) 9.46±0.40 9.50±0.35 0.375
52 Arch Osteoporos (2009) 4:47–53Conclusion
Our study confirms the high prevalence of hypovitaminosis
D in apparently healthy Indian women and shows that in a
tropical country like India, monthly oral administration of
60,000 IU cholecalciferol (~2,000 IU/day or 50 μg/day) is
effective in raising serum 25(OH)D to desired levels
(>30 ng/ml) during summer. However, higher doses of
cholecalciferol—120,000 IU/month administered orally
(~4,000 IU/day or 100 μg/day)—may be more appropriate
during winter. This may be an effective public health
strategy in severely deficient countries like India.
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